300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Enterprise
Community
Media (Entertainment)
Proptech
Hardware
Transportation
Biotech
Sustainability
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Aier Eye Hospital Group, VC Fund

Aier Eye Hospital Group

VC Fund

Changsha, China

Aier Eye Hospital Group is a VC fund in Changsha focused on Medical Device and Medical. Aier Eye Hospital Group offers surgery for myopia; prevention and treatment for myopia; treatment for cataract, glaucoma, pediatric ophthalmology, fundus disease, lacrimal disease, and cornea and ocular surface; and eye shaping beauty services.

Total investments:
10
Last investment:
Lead investor:
30%

Last updated:

Industries Aier Eye Hospital Group invests in

Medical DeviceMedicalSoftwareHealth CareBiotechnology

Stages Aier Eye Hospital Group invests in

Series ASeries BPost-IPO EquitySeedSeries C

Countries Aier Eye Hospital Group invests in

ChinaHong Kong

Contacts

NameEmailPhoneSocials
Bang Chen
Li Li
Michael Lau

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Medical Device 3 (30%)
  • Medical 2 (20%)
  • Software 2 (20%)
  • Health Care 2 (20%)
  • Biotechnology 2 (20%)
See all 18 industries →

Stage

  • Series A 2 (20%)
  • Series B 2 (20%)
  • Post-IPO Equity 2 (20%)
  • Seed 1 (10%)
  • Series C 1 (10%)
See all 7 stages →

Country

  • China 7 (70%)
  • Hong Kong 1 (10%)

Team

NameTitleInvestmentsLinksEmail
Bang Chen Founder
Founder Total investments: 0 Find email
Li Li Founder
Founder Total investments: 0 Find email
Michael Lau CEO
CEO Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Kangdesai Medical Technology Kangdesai Medical Technology
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrenceand metastasis. Series A / Sep 22, 2025
Sieran Medical
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. $14.1M / Seed / Sep 05, 2024
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. $43.1M / Series C / Mar 09, 2023
SIYO Bio-Tech SIYO Bio-Tech
SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology. $31.7M / Series B / Feb 23, 2022
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. Venture - Series Unknown / Dec 31, 2021
Zhaoke Ophthalmology Pharmaceutical Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform. $145M / Series B / Oct 12, 2020
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $5.1M / Post-IPO Equity / Mar 20, 2017
CloudClip CloudClip
CloudClip is a technology company that focuses on researching the myopia problem in young people and providing systematic solutions. They provide each user with customized eye-care training programs and help children develop a healthy eye-use habit. $1.4M / Series A / Dec 31, 2016
Qihoo 360 Technology Qihoo 360 Technology
Qihoo 360 Technology Co Ltd (Qihoo 360), formerly Qihoo Technology Company Limited, is engaged in the operations of Internet services and sales of third party anti-virus software in the People's Republic of China. It provides Internet and mobile security products in China. In January 2011, the Company had 328 million monthly active Internetsecurity product users, representing a user penetration rate of 83.9% in China. Its Internet and mobile security products include 360 Safe Guard and 360 Anti-virus, the Internet security products in China, with 301 million and 248 million monthly active users in January 2011, and 360 Mobile Safe, the mobile security product in China. The Company generates revenues primarily through offering the services, such as online advertising and Internet value-added services. Online advertising offers advertising services by providing marketing opportunities on its Websites and secure platform products to its advertising customers. $30M / Post-IPO Equity / Sep 28, 2016
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $7.1M / Series D / Jul 20, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Enterprise
Community
Media (Entertainment)
Proptech
Hardware
Transportation
Biotech
Sustainability
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Burkina Faso
Africa
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Colombia
Armenia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Aier Eye Hospital Group invest in?

Aier Eye Hospital Group invests primarily in Medical Device, Medical and Software startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Aier Eye Hospital Group?

Public channels for Aier Eye Hospital Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Aier Eye Hospital Group?

The team at Aier Eye Hospital Group includes Bang Chen (Founder), Li Li (Founder) and Michael Lau (CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Aier Eye Hospital Group Aier Eye Hospital Group Find emails